Mohamed Mohamed

Dr. Mohamed Mohamed


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HAHiba S. Al-Amodi
Hiba S. Al-Amodi
HBHanan Mosaad Bedair
Hanan Mosaad Bedair
SGSuzy Gohar
Suzy Gohar
MMMohamed Mohamed
Mohamed Mohamed
EGEman M. Abd El Gayed
Eman M. Abd El Gayed
SAShimaa Abdelsattar
Shimaa Abdelsattar
This study investigated the diagnostic, prognostic, and therapeutic significance of Fc receptor-like 1 (FCRL1) and B-cell activating factor (BAFF) mRNA expression in Egyptian patients with diffuse large B-cell lymphoma (DLBCL) undergoing the standard R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) using quantitative real-time PCR (RT-qPCR). The results demonstrated that FCRL1 and BAFF mRNA expression were significantly elevated in DLBCL patients compared to healthy controls. A strong positive correlation existed between BAFF and FCRL1 expression levels. Diagnostic performance assessed through combined ROC curve analysis revealed that BAFF, FCRL1, and lactate dehydrogenase (LDH) achieved perfect diagnostic accuracy (AUC = 1.0), demonstrating 100% sensitivity, specificity, and predictive values. Further prognostic analysis using COX regression identified elevated FCRL1 expression as the most significant predictor of poor clinical outcomes. Kaplan–Meier survival analysis reinforced this finding, with high FCRL1 expression showing significant associations with reduced overall survival (OS, p = 0.031) and progression-free survival (PFS, p = 0.038). The study underscores the potential utility of BAFF and FCRL1 mRNA as diagnostic markers for DLBCL, with FCRL1 emerging as a promising prognostic marker and potential therapeutic target enabling more tailored treatment approaches for DLBCL, the most common type of B-cell non-Hodgkin lymphoma, and patients receiving R-CHOP therapy.

Verified
Journal Article
Open access
PDF file
SAShimaa Abdelsattar
Shimaa Abdelsattar
HAHiba S. Al-Amodi
Hiba S. Al-Amodi
MNMahmoud Nazih
Mahmoud Nazih
ESEman Hosney Mohammed Salem
Eman Hosney Mohammed Salem
RMRasha G. Mostafa
Rasha G. Mostafa
MMMohamed Mohamed
Mohamed Mohamed
Sepsis-associated acute kidney injury (S-AKI) represents a significant health problem associated with adverse outcomes. Our study aimed to assess the value of serum cystatin-C (sCysC) and TNF-α (rs361525) in combination for diagnosing S-AKI patients and predicting their adverse outcomes. The study included 100 critically ill neonates and 100 controls. Patients were categorized into an S-AKI group and a non-AKI group. TNF-α (−238, rs361525) genotyping was performed using RT-PCR, and sCysC was assessed using ELISA. Our study showed a fundamental difference in the genotype frequencies of TNF-α (−238, rs361525) and SNP between S-AKI and non-AKI patients. Furthermore, there was a significant relationship between cystatin C and TNF-α (−238, rs361525), where cystatin C was higher in patients with AA alleles than in patients with GA and GG alleles. Combining GA + AA genotypes with elevated serum cystatin-C levels can serve as a potential diagnostic and prognostic biomarker for AKI development in this population. The GA/AA genotypes independently predicted S-AKI risk (OR = 6.64, p < 0.001). At the same time, elevated sCysC (>9.4 mg/L) emerged as a sensitive biomarker (AUC = 0.848) and independent predictor of adverse outcomes. Collectively, these findings contribute to the growing field of personalized medicine and represent a strategic advantage, enabling prevention-focused care rather than the treatment of established disease.

1 October 2021 in Journal of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MMMohamed Mohamed
Mohamed Mohamed
WEWael M. Elayat
Wael M. Elayat
AAAsmaa A. Abozeid
Asmaa A. Abozeid
MAMohamed F. Abdel-Salam
Mohamed F. Abdel-Salam
NTNahla Mohamed Teama
Nahla Mohamed Teama
YTYomna M. Tamim
Yomna M. Tamim
Background: Type 2 diabetes mellitus (DM) has many complications associated with increased morbidity and mortality. Cardiovascular complications are one of these serious complications. Therefore, there is a need for early and effective management to hamper them. This study aimed to evaluate the cardioprotective efficacy of metformin and myoinositol combination through exploring the associated underlying mechanisms in type 2 DM rat model. Methods: Type 2 DM model was induced in rats by streptozotocin and high-fat diet. Rats were treated with metformin (150 mg/kg) and/or myoinositol (50 mg/kg) by oral gavage once daily for 4 weeks. Immunohistochemistry was used to assess the drugs’ cardioprotective efficacy by estimating troponin T, nuclear factor kappa B (NF-kappaB) and tumor necrosis factor alpha (TNF-alpha). Quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay were utilized to investigate peroxisome proliferator-activated receptor-alpha (PPARalpha) and glucose transporter 4 (GLUT-4) expression levels in the skeletal muscles, respectively. Results: This study found that metformin and myoinositol combination was associated with GLUT-4 and PPARalpha overexpression, together with better lipid profile than metformin alone in diabetic rats. Additionally, the combination of both drugs improved troponin C and decreased creatine kinase MB isoenzyme, NF-kappaB and TNF-alpha cardiac levels. Conclusion: The current study indicated that myoinositol in combination with metformin had better cardioprotective effect than metformin alone in type 2 DM. This favorable effect was exhibited through upregulation of GLUT-4 and PPARalpha receptors expression in skeletal muscles, thus increasing insulin sensitivity and improving lipid profile. J Endocrinol Metab. 2021;11(5):140-151 doi: https://doi.org/10.14740/jem765

1 August 2021 in Annals of Neonatology Journal
Verified
Journal Article
Closed access
PDF file
WQWafaa Qsman
Wafaa Qsman
WKWalaa M. Kabiel
Walaa M. Kabiel
MMMohamed Mohamed
Mohamed Mohamed
Background: The levels of transplacental transferred immunoglobulin (Ig) carry protective effect to the neonate and varies by many factors as gestational age, maturity, body weight, hemodynamics and maternal diseases. Aim: This study aimed to measure the serum levels of Ig A and Ig G in neonates in different settings and to correlate their levels with neonatal morbidities. Methods: The study conducted during the period from June 2020 to January 2021 in a tertiary level NICU and included a total number of fifty one neonates. The measurement of serum Ig G and Ig A levels were measured by mininef method. Results: The mean value of Ig G and Ig A were 898 mg g/l and 16.3 g/l respectively. Ig G was directly correlated with the maturity, weight, early starting of feeding (p-value 0.001) while they correlated inversely with respiratory and inotropic support and CRP levels (p=value 0.001). Ig G was correlated inversely with the respiratory support whether CPAP or mechanical ventilation; being higher in neonates who didn't receive assisted ventilation. A cut off level of 512 g/l of Ig G was needed to detect increased risk of neonates to sepsis. Preterm babies had lower values than full term ones (p-value 0.001). Conclusion: Transplacental transferred immunoglobulins had a protective effect for neonates and their levels were inversely correlated with neonatal morbidities either in preterm or fullterm neonates

1 December 2021 in Gene Reports
Verified
Journal Article
Closed access
MMMohamed Mohamed
Mohamed Mohamed
ENEnas Samir Nabil
Enas Samir Nabil
FMFayda Ibrahim Abdel Motaleb
Fayda Ibrahim Abdel Motaleb
RARowaida M. Aboushahba
Rowaida M. Aboushahba
AAAhmed Abdel Aziz Abou-Zeid
Ahmed Abdel Aziz Abou-Zeid
SMShaimaa Mohamed Mohamed
Shaimaa Mohamed Mohamed